Abstracts tagged "clinical research and rheumatoid arthritis (RA)"

Abstract Number: 2517 • 2018 ACR/ARHP Annual Meeting
The JAK1-Selective Inhibitor Filgotinib Reverses the Disease-Associated Transcriptional Profile Found in the Blood of Patients with Active Rheumatoid Arthritis
Peter C. Taylor¹, Bryan Downie², Luting Zhuo², Yevgeniy Gindin², Jacqueline Tarrant³, Jinfeng Liu², René Galien⁴ and Amer M Mirza⁵, ¹University of Oxford Botnar Research Centre, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²Bioinformatics, Gilead Sciences Inc., Foster City, CA, ³Gilead Sciences Inc., Foster City, CA, ⁴Galapagos SASU, Romainville, France, ⁵Biomarker Sciences, Gilead Sciences Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), an oral JAK1- selective inhibitor, has shown good safety and efficacy in active rheumatoid arthritis (RA) patients with inadequate response to MTX…
Abstract Number: 452 • 2017 ACR/ARHP Annual Meeting
Time to First Treatment Is Associated with a Refractory Course of Rheumatoid Arthritis
Manuel Bécède¹, Farideh Alasti², Lukas Haupt³, Lisa Hütter³, Andreas Kerschbaumer⁴, Uriel Landesmann¹, Gabriela Supp⁴, Josef S. Smolen^4,5 and Daniel Aletaha⁶, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁴Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ⁵Department of Internal Medicine, Hietzing Hospital, Vienna, Austria, ⁶Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: It is an ongoing matter of research, whether the course of rheumatoid arthritis (RA) can be altered by an early intervention, a concept historically…
Abstract Number: 1708 • 2013 ACR/ARHP Annual Meeting
Can People With Rheumatoid Arthritis Self Monitor Their Disease Activity?
Noura AL Osaimi¹, Erin Carruthers², Charles H Goldsmith^3,4, Paul M Adam⁵ and Diane Lacaille^1,6, ¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Biostatistics, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁵Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: In rheumatoid arthritis (RA) the target for treatment is clinical remission or minimal disease activity. Active involvement of patients in monitoring their own disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].